Many companies have reported awards from the Qualifying Therapeutic Discovery Project Program this week and several Colorado companies are included.
Inviragen (Fort Collins) received two grants totaling $488,958 for ongoing programs to develop vaccines against dengue and chikungunya viruses.
GlobeImmune (Louisville) has been awarded three grants totaling $733,438 for three development programs: GI-5005 the company’s lead product [...]
Inviragen and Pharmajet announced that they received a five-year $15.5M contract from National Institute of Allergy and Infectious Diseases, part of the NIH, to advance development of a needle free dengue vaccine. The development will focus on combining Inviragen’s DENVax with Pharmajet’s needle-free delivery system. The funding is earmarked for pre-clinical testing, regulatory [...]
Inviragen, based in Fort Collins, Colorado and SingVax, based in Madison, Wisconsin, announced that they have merged and that the combined company has raised a $15M Series A round. Inviragen’s lead product candidate is a vaccine for dengue fever while SingVax brings potential vaccines for hand, foot and mouth disease and Japanese encephalitis. [...]
Inviragen announced that it has been awarded a $600,000 grant from the National Institute of Allergy and Infectious Disease to support the development of a Dengue fever vaccine. The grant will go towards a collaborative effort led by Inviragen and include scientists from the University of Wisconsin as well as the Division of Vector-Borne [...]
In the spirit of the holidays, Innovation After Hours focused on celebration of the successes and the contributions made to the Northern Colorado technology community. The program started with a thank you to outgoing Director of the Larimer Bioscience Cluster, Kathy Kregel. Kregel’s contributions to area startups include the four years she served [...]
|
|
| Mon | Tue | Wed | Thu | Fri | Sat | Sun |
|---|---|---|---|---|---|---|
| 1 | 2 | 3 | 4 | 5 | ||
| 6 | 7 | 8 | 9 | 10 | 11 | 12 |
| 13 | 14 | 15 | 16 | 17 | 18 | 19 |
| 20 | 21 | 22 | 23 | 24 | 25 | 26 |
| 27 | 28 | 29 | 30 | 31 | ||
Posting tweet...
Powered by Twitter Tools.
